Viridian Therapeutics (VRDN) Stock Overview
Engages in discovering, developing, and commercializing treatments for serious and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VRDN Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.38 |
| 52 Week High | US$34.29 |
| 52 Week Low | US$13.18 |
| Beta | 0.90 |
| 1 Month Change | 4.28% |
| 3 Month Change | -4.05% |
| 1 Year Change | 26.99% |
| 3 Year Change | -25.61% |
| 5 Year Change | 6.83% |
| Change since IPO | -89.88% |
Recent News & Updates
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
Summary Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results. I see significant upside potential from VRDN-008's phase 1 results and the FcRn pipeline (VRDN-006 and VRDN-008), and with the TSHR antibody offering longer-term expansion into Graves' disease. Read the full article on Seeking AlphaViridian Therapeutics (VRDN) Stock Could Be 84.84% Below Fair Value After Institutional Buying
Viridian Therapeutics (VRDN) is back on investors' radar after a rise in institutional ownership and strong year over year gains in quarterly revenue and net profit, which has drawn fresh attention to the stock. See our latest analysis for Viridian Therapeutics. At a share price of $16.63, Viridian Therapeutics has seen its 7 day and 30 day share price returns of 3.04% and 4.13% contrast with a much weaker 90 day share price return, while a 1 year total shareholder return of 10.87% sits...Recent updates
Shareholder Returns
| VRDN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.3% | 6.1% | 0.3% |
| 1Y | 27.0% | 40.6% | 19.9% |
Return vs Industry: VRDN underperformed the US Biotechs industry which returned 40.6% over the past year.
Return vs Market: VRDN exceeded the US Market which returned 19.9% over the past year.
Price Volatility
| VRDN volatility | |
|---|---|
| VRDN Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VRDN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRDN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 252 | Steve Mahoney | www.viridiantherapeutics.com |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED.
Viridian Therapeutics, Inc. Fundamentals Summary
| VRDN fundamental statistics | |
|---|---|
| Market cap | US$2.07b |
| Earnings (TTM) | -US$303.27m |
| Revenue (TTM) | US$70.92m |
Is VRDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRDN income statement (TTM) | |
|---|---|
| Revenue | US$70.92m |
| Cost of Revenue | US$339.64m |
| Gross Profit | -US$268.72m |
| Other Expenses | US$34.55m |
| Earnings | -US$303.27m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.75 |
| Gross Margin | -378.92% |
| Net Profit Margin | -427.63% |
| Debt/Equity Ratio | 7.9% |
How did VRDN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 21:58 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Viridian Therapeutics, Inc. is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Leah Rush Cann | Brookline Capital Markets |
| Jason Butler | Citizens JMP Securities, LLC |